Last10K.com

Cynosure Inc (CYNO) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Cynosure Inc

HISTORY TOOLS
CIK: 885306 Ticker: CYNO

Exhibit 99.1

 

LOGO

Cynosure Achieves Record Quarterly Revenue of $122.1 Million in

the Fourth Quarter of 2016, Up 19 Percent Year-over-Year

Fourth-Quarter 2016 Highlights:

 

  •   North American product revenue up 24 percent to $69.5 million

 

  •   International product revenue up 12 percent to $33.2 million

 

  •   GAAP earnings of $0.09 per diluted share includes $7.2 million charge related to previously disclosed TCPA litigation settlement agreement

 

  •   Non-GAAP earnings of $0.44 per diluted share

 

  •   Cash and investments of $237.8 million at December 31, 2016

Full-Year 2016 Highlights:

 

  •   Record annual revenue of $433.5 million, up 28 percent year-over-year

 

  •   GAAP earnings of $0.65 per diluted share includes $7.2 million charge related to previously disclosed TCPA litigation settlement agreement

 

  •   Non-GAAP earnings of $1.28 per diluted share

 

  •   Cash flow from operations of $45.0 million

Westford, MA, February 7, 2017 – Cynosure, Inc. (Nasdaq: CYNO) today reported fourth-quarter and full-year 2016 financial results.

Michael Davin, Cynosure President and CEO, said, “We capped an outstanding year with a strong fourth quarter, as revenue increased 19 percent year-over-year to a quarterly record $122.1 million. The fourth quarter of 2016 marked our 28th consecutive quarter of year-over-year top-line growth, an accomplishment that demonstrates the enduring strength and consistent quality of our product portfolio. We continue to lead the aesthetic device industry by focusing on innovation, execution and growth. The 23 percent compound annual top-line growth we’ve achieved over the past five years reflects our ability to cultivate the right organic opportunities, make disciplined strategic investments and maintain a solid financial model.”

Davin added, “SculpSure®, our unique laser treatment for non-invasive fat destruction, continues to outpace expectations. In the fourth quarter of 2016, we placed the highest number of SculpSure units in a quarter since we launched the device in late 2015. MonaLisa Touch®, our first aesthetic laser product for women’s health, also performed well, recording the second-highest unit placements in a quarter in its history. More than 70 percent of SculpSure sales in the quarter came from the non-core physician market. Bundled sales of multiple products increased to 31 percent of revenues during the

The following information was filed by Cynosure Inc (CYNO) on Tuesday, February 7, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Cynosure Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cynosure Inc.

Continue

Assess how Cynosure Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Cynosure Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (parenthetical)
401(k) Plan
401(k) Plans - Additional Information (detail)
Balance Sheet Accounts
Balance Sheet Accounts (tables)
Balance Sheet Accounts - Accrued Expenses (detail)
Balance Sheet Accounts - Additional Information (detail)
Balance Sheet Accounts - Other Noncurrent Liabilities (detail)
Balance Sheet Accounts - Property And Equipment (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Operating Facility, Certain Equipment And Vehicles Under Operating Lease And Capital Lease Agreements With Payments (detail)
Fair Value
Fair Value (tables)
Fair Value - Measurement Of Fair Value Hierarchy For Financial Assets (detail)
Goodwill And Other Intangible Assets
Goodwill And Other Intangible Assets (tables)
Goodwill And Other Intangible Assets - Additional Information (detail)
Goodwill And Other Intangible Assets - Schedule Of Amortization Expenses On Intangible Assets (detail)
Goodwill And Other Intangible Assets - Schedule Of Changes To Goodwill (detail)
Goodwill And Other Intangible Assets - Schedule Of Components Of Other Intangible Assets (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Changes In Gross Unrecognized Tax Benefits (detail)
Income Taxes - Income Before Income Tax Provision (benefit) (detail)
Income Taxes - Provision (benefit) For Income Taxes (detail)
Income Taxes - Reconciliation Of Federal Statutory Rate (detail)
Income Taxes - Significant Components Of Deferred Tax Assets And Liabilities (detail)
Nature Of The Business
Nature Of The Business - Additional Information (detail)
Segment And Geographic Information
Segment And Geographic Information (tables)
Segment And Geographic Information - Additional Information (detail)
Segment And Geographic Information - Schedule Of Long-lived Assets (property And Equipment Only) By Geographic Area (detail)
Segment And Geographic Information - Schedule Of Total Assets By Geographic Area (detail)
Segment And Geographic Information - Schedule Of Total Revenue By Geographic Destination (detail)
Short And Long-term Marketable Securities
Short And Long-term Marketable Securities (tables)
Short And Long-term Marketable Securities - Additional Information (detail)
Short And Long-term Marketable Securities - Schedule Of Available-for-sale Debt Securities Mature (detail)
Short And Long-term Marketable Securities - Schedule Of Marketable Securities (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Stock Option Activity (detail)
Stock-based Compensation - Summary Of Psus Activity Under 2005 Plan (detail)
Stock-based Compensation - Summary Of Rsu Grant And Unrecognized Compensation Expense (detail)
Stock-based Compensation - Summary Of Rsus Activity Under 2005 Plan (detail)
Stockholders' Equity
Stockholders' Equity - Additional Information (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Accounts Receivable Allowance Activity (detail)
Summary Of Significant Accounting Policies - Activity In The Accrued Warranty Account (detail)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Changes To Accumulated Other Comprehensive Loss (detail)
Summary Of Significant Accounting Policies - Inventories (detail)
Summary Of Significant Accounting Policies - Schedule Of Reconciliation Of Basic And Diluted Shares (detail)
Summary Of Significant Accounting Policies - Summary Of Share-based Compensation Arrangement Fair Value Assumptions (detail)
Summary Of Significant Accounting Policies - Summary Of Stock-based Compensation Expenses (detail)
Summary Selected Quarterly Financial Data (unaudited)
Summary Selected Quarterly Financial Data (unaudited) (tables)
Summary Selected Quarterly Financial Data (unaudited) - Unaudited Consolidated Quarterly Results Of Operations (detail)
Ticker: CYNO
CIK: 885306
Form Type: 10-K Annual Report
Accession Number: 0001193125-17-062692
Submitted to the SEC: Tue Feb 28 2017 5:20:21 PM EST
Accepted by the SEC: Tue Feb 28 2017
Period: Saturday, December 31, 2016
Industry: Electromedical And Electrotherapeutic Apparatus

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/cyno/0001193125-17-062692.htm